Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria

Nami Shrestha Palikhe, Seung Hyun Kim, Young Min Ye, Gyu Young Hur, Bo Young Cho, Hae Sim Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Chronic urticaria (CU), defined as the recurring incidence of wheals with or without angioedema for more than 6 weeks, is a common disorder associated with mast cell activation, degranulation, and histamine release. Considering the association between the CRTH2 gene and mast cells, we investigated the association of this gene polymorphism with the CU phenotype and antihistamine drug requirement in patients with CU. Materials & methods: Two groups consisting of 384 patients with CU and 231 patients as normal controls (NCs) were enrolled from the Department of Allergy and Rheumatology, Ajou University Hospital, Suwon, Korea. Two polymorphisms of the CRTH2 gene, -466T>C and -129C>A were genotyped using primer extension methods. Results: No significant differences were detected in the genotype and allele frequencies of the two CRTH2 polymorphisms between the CU and NC groups, and no significant associations were observed with clinical parameters, such as atopy status, serum total IgE, prevalence of autoantibodies and duration of CU. However, CU patients with homozygous TT genotypes had significantly higher dose requirements of antihistamines to control the CU symptoms (164.56 ± 115.62 vs 137.38 ± 90.15 loratadine equivalents, mg/week) than those with the CT and CC genotypes (p = 0.025). The luciferase activity was significantly enhanced in the construct containing CRTH2 466C compared with the -466T-containing construct (p < 0.001). Co-transfection experiments with GATA-3 (300 ng) and the -466T and -466C CRTH2 alleles revealed that the CRTH2 -466T allele produced a greater increase in induction of luciferase activity than the -466C allele (p < 0.001). Conclusion: The CRTH2 -466T>C gene polymorphism may not affect on the phenotype of CU, but contributes to the required dose of antihistamines in patients with CU.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalPharmacogenomics
Volume10
Issue number3
DOIs
Publication statusPublished - 2009 Jun 16
Externally publishedYes

Fingerprint

Histamine Antagonists
Urticaria
Genes
Genotype
Mast Cells
Loratadine
Phenotype
Cell Degranulation
Angioedema
Histamine Release
Rheumatology
Korea
Luciferases
Gene Frequency
Autoantibodies
Immunoglobulin E
Hypersensitivity
Control Groups

Keywords

  • Antihistamine drugs
  • Chronic urticaria
  • CRTH2
  • Polymorphism

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. / Palikhe, Nami Shrestha; Kim, Seung Hyun; Ye, Young Min; Hur, Gyu Young; Cho, Bo Young; Park, Hae Sim.

In: Pharmacogenomics, Vol. 10, No. 3, 16.06.2009, p. 375-383.

Research output: Contribution to journalArticle

Palikhe, Nami Shrestha ; Kim, Seung Hyun ; Ye, Young Min ; Hur, Gyu Young ; Cho, Bo Young ; Park, Hae Sim. / Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. In: Pharmacogenomics. 2009 ; Vol. 10, No. 3. pp. 375-383.
@article{97d35c773d7445d88e8178047db2334d,
title = "Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria",
abstract = "Introduction: Chronic urticaria (CU), defined as the recurring incidence of wheals with or without angioedema for more than 6 weeks, is a common disorder associated with mast cell activation, degranulation, and histamine release. Considering the association between the CRTH2 gene and mast cells, we investigated the association of this gene polymorphism with the CU phenotype and antihistamine drug requirement in patients with CU. Materials & methods: Two groups consisting of 384 patients with CU and 231 patients as normal controls (NCs) were enrolled from the Department of Allergy and Rheumatology, Ajou University Hospital, Suwon, Korea. Two polymorphisms of the CRTH2 gene, -466T>C and -129C>A were genotyped using primer extension methods. Results: No significant differences were detected in the genotype and allele frequencies of the two CRTH2 polymorphisms between the CU and NC groups, and no significant associations were observed with clinical parameters, such as atopy status, serum total IgE, prevalence of autoantibodies and duration of CU. However, CU patients with homozygous TT genotypes had significantly higher dose requirements of antihistamines to control the CU symptoms (164.56 ± 115.62 vs 137.38 ± 90.15 loratadine equivalents, mg/week) than those with the CT and CC genotypes (p = 0.025). The luciferase activity was significantly enhanced in the construct containing CRTH2 466C compared with the -466T-containing construct (p < 0.001). Co-transfection experiments with GATA-3 (300 ng) and the -466T and -466C CRTH2 alleles revealed that the CRTH2 -466T allele produced a greater increase in induction of luciferase activity than the -466C allele (p < 0.001). Conclusion: The CRTH2 -466T>C gene polymorphism may not affect on the phenotype of CU, but contributes to the required dose of antihistamines in patients with CU.",
keywords = "Antihistamine drugs, Chronic urticaria, CRTH2, Polymorphism",
author = "Palikhe, {Nami Shrestha} and Kim, {Seung Hyun} and Ye, {Young Min} and Hur, {Gyu Young} and Cho, {Bo Young} and Park, {Hae Sim}",
year = "2009",
month = "6",
day = "16",
doi = "10.2217/14622416.10.3.375",
language = "English",
volume = "10",
pages = "375--383",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria

AU - Palikhe, Nami Shrestha

AU - Kim, Seung Hyun

AU - Ye, Young Min

AU - Hur, Gyu Young

AU - Cho, Bo Young

AU - Park, Hae Sim

PY - 2009/6/16

Y1 - 2009/6/16

N2 - Introduction: Chronic urticaria (CU), defined as the recurring incidence of wheals with or without angioedema for more than 6 weeks, is a common disorder associated with mast cell activation, degranulation, and histamine release. Considering the association between the CRTH2 gene and mast cells, we investigated the association of this gene polymorphism with the CU phenotype and antihistamine drug requirement in patients with CU. Materials & methods: Two groups consisting of 384 patients with CU and 231 patients as normal controls (NCs) were enrolled from the Department of Allergy and Rheumatology, Ajou University Hospital, Suwon, Korea. Two polymorphisms of the CRTH2 gene, -466T>C and -129C>A were genotyped using primer extension methods. Results: No significant differences were detected in the genotype and allele frequencies of the two CRTH2 polymorphisms between the CU and NC groups, and no significant associations were observed with clinical parameters, such as atopy status, serum total IgE, prevalence of autoantibodies and duration of CU. However, CU patients with homozygous TT genotypes had significantly higher dose requirements of antihistamines to control the CU symptoms (164.56 ± 115.62 vs 137.38 ± 90.15 loratadine equivalents, mg/week) than those with the CT and CC genotypes (p = 0.025). The luciferase activity was significantly enhanced in the construct containing CRTH2 466C compared with the -466T-containing construct (p < 0.001). Co-transfection experiments with GATA-3 (300 ng) and the -466T and -466C CRTH2 alleles revealed that the CRTH2 -466T allele produced a greater increase in induction of luciferase activity than the -466C allele (p < 0.001). Conclusion: The CRTH2 -466T>C gene polymorphism may not affect on the phenotype of CU, but contributes to the required dose of antihistamines in patients with CU.

AB - Introduction: Chronic urticaria (CU), defined as the recurring incidence of wheals with or without angioedema for more than 6 weeks, is a common disorder associated with mast cell activation, degranulation, and histamine release. Considering the association between the CRTH2 gene and mast cells, we investigated the association of this gene polymorphism with the CU phenotype and antihistamine drug requirement in patients with CU. Materials & methods: Two groups consisting of 384 patients with CU and 231 patients as normal controls (NCs) were enrolled from the Department of Allergy and Rheumatology, Ajou University Hospital, Suwon, Korea. Two polymorphisms of the CRTH2 gene, -466T>C and -129C>A were genotyped using primer extension methods. Results: No significant differences were detected in the genotype and allele frequencies of the two CRTH2 polymorphisms between the CU and NC groups, and no significant associations were observed with clinical parameters, such as atopy status, serum total IgE, prevalence of autoantibodies and duration of CU. However, CU patients with homozygous TT genotypes had significantly higher dose requirements of antihistamines to control the CU symptoms (164.56 ± 115.62 vs 137.38 ± 90.15 loratadine equivalents, mg/week) than those with the CT and CC genotypes (p = 0.025). The luciferase activity was significantly enhanced in the construct containing CRTH2 466C compared with the -466T-containing construct (p < 0.001). Co-transfection experiments with GATA-3 (300 ng) and the -466T and -466C CRTH2 alleles revealed that the CRTH2 -466T allele produced a greater increase in induction of luciferase activity than the -466C allele (p < 0.001). Conclusion: The CRTH2 -466T>C gene polymorphism may not affect on the phenotype of CU, but contributes to the required dose of antihistamines in patients with CU.

KW - Antihistamine drugs

KW - Chronic urticaria

KW - CRTH2

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=65649145676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649145676&partnerID=8YFLogxK

U2 - 10.2217/14622416.10.3.375

DO - 10.2217/14622416.10.3.375

M3 - Article

C2 - 19290788

AN - SCOPUS:65649145676

VL - 10

SP - 375

EP - 383

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 3

ER -